PKD2 is one of the two genes mutated in ADPKD (autosomal-dominant polycystic kidney disease). The protein product of PKD2, polycystin-2, functions as a non-selective cation channel in the endoplasmic reticulum and possibly at the plasma membrane. Hydrophobicity plots and its assignment to the TRP (transient receptor potential) family of cation channels suggest that polycystin-2 contains six transmembrane domains and that both the N- and C-termini extend into the cytoplasm. However, no experimental evidence for this model has so far been provided. To determine the orientation of the different loops of polycystin-2, we truncated polycystin-2 within the predicted loops 1–5 and tagged the constructs at the C-terminus with an HA (haemagglutinin) epitope. After transient expression and selective membrane permeabilization, immunofluorescence staining for the HA epitope revealed that loops 1, 3 and 5 extend into the lumen of the endoplasmic reticulum or the extracellular space, whereas loops 2 and 4 extend into the cytoplasm. This approach also confirmed the cytoplasmic orientation of the N- and C-termini of polycystin-2. In accordance with the immunofluorescence data, protease protection assays from microsomal preparations yielded protected fragments when polycystin-2 was truncated in loops 1, 3 and 5, whereas no protected fragments could be detected when polycystin-2 was truncated in loops 2 and 4. The results of the present study therefore provide the first experimental evidence for the topological orientation of polycystin-2.
- membrane topology
- transient receptor potential family
At a prevalence of at least 1:1000, ADPKD [autosomal-dominant PKD (polycystic kidney disease)] is one of the most common inherited human diseases . The main symptom of ADPKD is cyst formation within the kidney parenchyma, but additional symptoms, such as liver and pancreatic cysts, heart valve defects and aneurysms, are common. In total, 85% of the patients carry mutations in the PKD1 gene, and the remaining 15% suffer from mutations in the PKD2 gene [2–5]. The protein encoded by PKD1, polycystin-1, is a transmembrane protein encompassing 4302 amino acids [6–8], 11 transmembrane domains, an extracellular N-terminus and a cytoplasmic C-terminus . Polycystin-2, the protein product of the PKD2 gene, is an integral membrane protein of 968 amino acids with a predicted molecular mass of 110 kDa [10,11]. It functions as a non-selective channel for mono- and bi-valent cations, and its activity is regulated by Ca2+ ions , probably through an EF-hand domain within the C-terminal domain [13,14]. The subcellular location of polycystin-2 is discussed controversially. Beside its location in the ER (endoplasmic reticulum), attributed to a 34-amino-acid cluster in the C-terminus , polycystin-2 may also be present at the plasma membrane . It is generally accepted, however, that polycystin-2 is integrated in the plasma membrane of the primary cilium [16,17]. This pathway is regulated by a trafficking motif located within the first 15 amino acids of the protein .
The close homology of polycystin-2 with the TRP (transient receptor potential) family of cation channels suggests that polycystin-2 consists of six transmembrane domains with both the N- and C-terminus extending into the cytoplasm. In the absence of crystallography data for this membrane protein and in order to gain structural information which might help to better understand its function, we determined the topology of polycystin-2 by molecular and biochemical approaches.
MATERIALS AND METHODS
Expression plasmids and transfections
The full-length human PKD2 cDNA (a gift from Dr Stefan Somlo, Yale University, New Haven, CT, U.S.A.) was subcloned into the eukaryotic expression vector pcDNA3 (Invitrogen). Various expression constructs were generated which coded for polycystin-2 proteins of 460, 493, 547, 577, 582 and 625 amino acids in length respectively. In most cases an HA (haemagglutinin) epitope was fused to the C-terminus of the proteins (Table 1).
COS-7 cells were maintained in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10% FBS (fetal bovine serum). They were transiently transfected at a confluency of 70–80% with 15 μg of DNA per 60-mm dish using the DEAE-dextran protocol .
All manipulations were carried out at 4 °C. Five 100-mm dishes with COS-7 cells were transiently transfected with the respective expression plasmids. Cells were washed three times 48 h later with 1×PBS, scraped off of the dishes and centrifuged for 15 min at 200 g at 4 °C. The cell pellet was resuspended in buffer A [10 mM Hepes/KOH (pH 7.4), 10 mM KCl, 1.5 mM MgCl2, 5 mM sodium EDTA, 5 mM EGTA and 250 mM sucrose], incubated for 15 min and then homogenized with 20 strokes in a Dounce homogenizer. Nuclei and intact cells were removed by centrifugation for 30 min at 1000 g. The supernatant was cleaned once more by centrifugation for 15 min at 1000 g before membrane vesicles were collected by centrifugation for 30 min at 55000 rev./min (Beckman Coulter TLA-55). This microsomal fraction was finally resuspended in buffer B [10 mM Hepes/KOH (pH 7.4), 10 mM KCl, 1.5 mM MgCl2, 5 mM sodium EDTA, 5 mM EGTA, 250 mM sucrose and 100 mM NaCl].
Protease protection assay
The microsomal preparation (in buffer B) was divided into two halves and centrifuged again at 55000 rev./min (Beckman Coulter TLA-55) for 30 min. Subsequently, one pellet was resuspended in buffer B containing 1% Triton X-100 and the other pellet in buffer B only. The resuspended vesicles were incubated for 1 h at 4 °C in the presence or absence of 1 mg/ml proteinase K [except in the case of polycystin-2 (loop 3)–HA when 4 mg/ml proteinase K was used]. A control reaction in buffer B without Triton X-100 was performed in parallel. Reactions were stopped by incubating in 5 mM PMSF for 20 min at room temperature (20 °C), and analysed by immunoprecipitation, as described below.
PNGase F (peptide N-glycosidase F) assay
Proteinase K-treated and untreated microsomal preparations of transiently transfected COS-7 cells synthesizing polycystin-2 (loop 1)–HA were denatured for 10 min at 100 °C in 1×denaturing buffer (New England Biolabs) as recommended in the manufacturer's instructions. Samples were then supplemented with (final concentration) 1% Nonidet P40 and 1×G7 buffer (New England Biolabs) and incubated with 8.3 units/μl of PNGase F (New England Biolabs) for 90 min at 37 °C; control samples were incubated without PNGase F. Finally, the deglycosylated proteins were subjected to immunoprecipitation as described below.
For immunoprecipitations, non-permeabilized samples from the protease protection assays were first permeabilized for 30 min on ice by adding 1% Triton X-100 (final concentration). The reactions were performed in 600 μl of buffer B containing 20 μl of Protein A–Sepharose beads (GE Healthcare) coupled with the monoclonal anti-(HA epitope) antibody 12CA5 (500 μl of hybridoma supernatant per 20 μl of beads). Immunoprecipitations were performed for 4 h at 4 °C on a rotating wheel, then the beads were briefly spun down, washed four times in buffer B and resuspended in an equal volume of 2×sample buffer. Supernatants obtained after the immunoprecipitation were kept for later Western blot analysis.
Western blot analysis
Total cell lysates were prepared 48 h after the transient transfection of COS-7 cells. The cells were washed three times with 1×PBS, scraped off the Petri dishes and centrifuged for 15 minutes at 200 g and 4 °C. Afterwards, the cell pellet was lysed in 1×PBS, 1% Triton X-100, 10 μg/ml aprotinin, 10 μg/ml leupeptin and 0.5 mM PMSF, and the protein concentration was determined using the Bradford assay. Total protein or immunoprecipitated protein (30 μg) were subjected to denaturing PAGE before being transferred on to a PVDF membrane (Millipore). The membrane was incubated with one of the following primary antibodies: the rat monoclonal anti-(HA epitope) antibody 3F10 (Roche Diagnostics; diluted 1:4000), a rabbit polyclonal anti-calreticulin antibody (Stressgen; diluted 1:2000) and a rabbit polyclonal anti-actin antibody (Sigma; diluted 1:2500). The following secondary antibodies were used: HRP (horseradish peroxidase)-conjugated anti-(rabbit IgG) (Sigma; diluted 1:20000) and HRP-conjugated anti-rat IgG (Dianova; diluted 1:20000).
For immunofluorescence labelling, cells were fixed for 1 h at room temperature with Bouin's solution [0.1 M sodium phosphate (pH 7.4), 15% saturated picric acid and 2% formaldehyde], washed three times with 1×PBS, and permeabilized for 15 min with 0.25% Triton X-100 at room temperature or with 5 μg/ml digitonin at 4 °C. Fixation of non-permeabilized cells was performed for 1 h at room temperature with 1×PBS and 4% paraformaldehyde, then cells were washed three times in 1×PBS, and blocked with 1×PBS/2% BSA for 1 h at room temperature. The fixed cells were incubated with the primary antibodies (diluted in 1×PBS/2% BSA) for 2 h at room temperature. After the cells were washed once with high-salt 1×PBS (total concentration of 500 mM NaCl) and twice with 1×PBS, they were incubated with the secondary antibodies (diluted in 1×PBS/2% BSA) for 1 h at room temperature. The cells were washed again with high-salt and regular 1×PBS before the nuclei were stained for 1 min at room temperature with 10 μg/ml Hoechst 33258. Finally the cells were washed three times with 1×PBS and mounted in 1×PBS and 40% glycerol. Images were acquired using a Zeiss LSM 710 confocal laser-scanning microscope and processed with Adobe Photoshop. The following primary antibodies were used: a mouse monoclonal anti-(acetylated tubulin) antibody (Sigma; diluted 1:200); a rabbit polyclonal antiserum raised against the peptide N-CSIPQDLRDEIKE-C (amino acids 331–343 of human polycystin-2) (diluted 1:100), the mouse monoclonal anti-(HA epitope) antibody 12CA5 (hybridoma supernatant; diluted 1:30), a polyclonal anti-(HA epitope) antibody (Sigma; diluted 1:100), the mouse monoclonal anti-CD8 antibody OKT8 (hybridoma supernatant; diluted 1:30), a mouse monoclonal anti-calnexin antibody (BD Biosciences; diluted 1:30), and the rabbit polyclonal anti-polycystin-2 antiserum YCB9 directed against amino acids 103–203 of human polycystin-2 (diluted 1:4000). The following secondary antibodies were used: FITC-conjugated anti-mouse IgG (ICN Biomedicals; diluted 1:200), Cy3 (indocarbocyanine)-conjugated anti-(mouse IgG) (Dianova; diluted 1:300) and Cy3-conjugated anti-(rabbit IgG) (Dianova; diluted 1:400).
Determining the topology of polycystin-2 by immunofluorescence
According to two hydrophobicity plot-based structural predictions ( and Swiss-Prot database accession number Q13563), the polycystin-2 protein contains six transmembrane domains, with the N-terminus and the C-terminus extending into the cytoplasm (Figure 1). Although both models show minor differences with respect to the position of transmembrane domains 1, 2, 3, 5 and 6, they diverge markedly on the first and last amino acid positions of the fourth transmembrane helix (Figure 1). To elucidate the topology of polycystin-2 experimentally and to better characterize the position of its transmembrane domains and loops, we examined full-length and C-terminal truncation mutants of polycystin-2 tagged at the C-terminus with an HA epitope (Figure 2). Upon transient transfection into COS-7 cells, the cellular location (plasma membrane or ER) of the HA-epitope-tagged proteins was determined with an anti-(HA epitope) antibody in the presence of selective permeabilization agents such as digitonin and Triton X-100. Digitonin allows the specific permeabilization of the plasma membrane, whereas Triton X-100 permeabilizes all cellular membranes . The specificity of the selective permeabilization treatments was verified by immunofluorescence using an antibody against a cytoplasmic protein (acetylated tubulin) and an antibody against a protein located in the lumen of the ER (calnexin).
To first verify whether the N- and C-termini of polycystin-2 extend into the cytoplasm as postulated by structural predictions, COS-7 cells were transiently transfected with a construct coding for the full-length polycystin-2 protein tagged with a C-terminal HA epitope (Figure 2). At 48 h after transfection, cells were fixed and incubated either with a monoclonal anti-(HA epitope) antibody or with a polyclonal antibody directed against amino acids 103–203 of polycystin-2 (Figure 3). In either case, the full-length protein was already detectable in digitonin-permeabilized cells (Figure 3) which confirms the predicted cytoplasmic location of the N- and C-termini of full-length polycystin-2. Our experimental approach was validated by control staining for acetylated tubulin and calnexin. A tubulin signal was detected in digitonin- and Triton X-100-permeabilized cells, but not in non-permeabilized cells (Figure 3), whereas calnexin was first visible after permeabilizing the cells with Triton X-100 (Figure 3).
We next focused on elucidating the orientation of the five putative loops of polycystin-2 using the same indirect immunofluorescence approach. For that purpose, progressive C-terminal deletions of polycystin-2 were generated which ended within the predicted loops and which were tagged with an HA epitope at the C-terminus (Figure 2). All five truncated proteins were detected by Western blot analysis (Supplementary Figure S1 at http://www.BiochemJ.org/bj/433/bj4330285add.htm). Since these proteins lack the C-terminal retention signal for the ER they were expected to reach the plasma membrane, and (depending on the orientation of the respective loop) should be detectable in either non-permeabilized or digitonin-treated cells. Polycystin-2 mutant proteins truncated in loops 4 and 5 indeed reached the plasma membrane (Figure 4), which was confirmed by double-immunofluorescence staining for the plasma membrane marker CD8 (Supplementary Fig-ure S2 at http://www.BiochemJ.org/bj/433/bj4330285add.htm). In contrast, polycystin-2 proteins truncated in loops 1, 2 and 3 did not reach the plasma membrane and were retained intracellularly, which was evident by a cytoplasmic staining pattern upon either digitonin or Triton X-100 treatment (Figure 4) similar to that observed for the full-length protein (Figure 3). This intracellular location was confirmed by the absence of co-localization with the plasma membrane marker CD8 (Supplementary Figure S2 and results not shown). These observations argue for the presence of a plasma membrane export signal between amino acids 547 and 582 (H. Hoffmeister, K. Babinger, S. Gürster, A. Cedzich, C. Meese, K. Schadendorf, L. Osten, U. de Vries, A. Rascle and R. Witzgall, unpublished work).
In spite of the different locations of the truncated polycystin-2 proteins, selective permeabilization allowed us to determine the orientation of the respective loops by immunofluorescence. In COS-7 cells synthesizing the mutant truncated in loop 5, an immunofluorescence signal was already detected without permeabilization (Figure 4), which argued that this loop extends into the extracellular space. Both the loop 4 mutant (which reaches the plasma membrane) and the loop 2 mutant (which is retained intracellularly) were first detected after digitonin treatment (Figure 4). This result argued for a cytoplasmic orientation of both loops. Permeabilization of COS-7 cells with Triton X-100 finally allowed the detection of the polycystin-2 mutant proteins truncated in loop 1 and loop 3 respectively (Figure 4), which demonstrates that both loops extend into the lumen of the ER. The orientation of loop 1 was also verified using an antibody directed against amino acids 331–341 (loop 1) (Figure 5). A polycystin-2 mutant protein located in the plasma membrane was already detected with this antibody in non-permeabilized cells (Figure 5), thus arguing that loop 1 extends into the extracellular space. A similar pattern was observed with this antibody upon synthesis of the same polycystin-2 fragment lacking the C-terminal HA epitope (Figure 5), which makes it unlikely that the HA epitope influences the overall topology of the C-terminal deletion mutants. Our immunofluorescence data are therefore compatible with the model: (i) that polycystin-2 contains six transmembrane domains, (ii) that its N- and C-termini extend into the cytoplasm, (iii) that its loops 1, 3 and 5 extend into the lumen of the ER and the extracellular space respectively, and (iv) that its loops 2 and 4 extend into the cytoplasm.
Determining the topology of polycystin-2 using protease protection assays
To verify the immunofluorescence data, protease protection assays were performed on microsomal preparations of transiently transfected COS-7 cells producing the truncated polycystin-2 mutant proteins. Microsomes are membrane vesicles with cytoplasmic-side-out orientation . Protease treatment of non-permeabilized microsomes will therefore exclusively digest protein domains which extend into the cytosol, whereas protein domains exposed to the microsomal lumen (lumen of the ER and extracellular space) are protected. Assuming that proteinase K cleaves polycystin-2 after amino acid 221 (within the N-terminus, immediately preceding the first residue of the first transmembrane domain), amino acids 492 and 503 (within putative loop 2) and amino acids 571 and 598 (within putative loop 4), one would expect protected fragments with molecular masses of ~28.9 kDa, 6.6–8.0 kDa and 4.7–7.8 kDa respectively, upon proteinase K digestion in the absence of detergent for the loop 1, loop 3 and loop 5 constructs (Figure 6). Protease protection assays were performed with microsomes in the absence and presence of 1% Triton X-100 and in the absence and presence of proteinase K. Protected fragments were immunoprecipitated with the murine monoclonal anti-(HA epitope) antibody 12CA5 and detected by Western blot analysis with the rat monoclonal anti-(HA epitope) antibody 3F10. The integrity of the microsomal preparations was controlled by Western blot analysis of the post-immunoprecipitation supernatants using an antibody directed against the luminal ER protein calreticulin. As predicted, calreticulin was only degraded by proteinase K when Triton X-100 was added to the microsomal fractions (Figure 7a, lane 4). Proteinase K cleavage of non-permeabilized vesicles from cells producing polycystin-2 (loop 1)–HA yielded a protected fragment (Figure 7a, lane 2) and therefore corroborated the immunofluorescence data that loop 1 extended into the lumen of the ER. However, the observed molecular mass of the protected fragment (~40 kDa) exceeded the expected size markedly. Since full-length polycystin-2 is known to be N-glycosylated [10,22,23], possibly at five predicted glycosylation sites within loop 1, we investigated whether the higher molecular mass of the protected fragment was due to glycosylation. Microsomal preparations of cells synthesizing polycystin-2 (loop 1)–HA were incubated with the enzyme PNGase F which cleaves all N-glycosidic bonds. Upon PNGase F treatment, the polycystin-2 (loop 1)–HA protein migrated with a markedly higher mobility (Figure 7b, lane 2), thus confirming that loop 1 is glycosylated. PNGase F treatment of proteinase K-digested polycystin-2 (loop 1)–HA generated a protected fragment of ~28 kDa (Figure 7c, lane 2), which again is close to the predicted molecular mass of 28.9 kDa (Figure 6). These data thus confirm that loop 1 of polycystin-2 is N-glycosylated and that it extends into the lumen of the ER. By inference, the higher apparent molecular mass of polycystin-2 (loop 2)–HA and (loop 3)–HA proteins (Supplementary Figure S1, lanes 1–3) is probably due to glycosylation within loop 1.
Analogous protease protection assays were performed from microsomal preparations of COS-7 cells producing polycystin-2 (loop 3)–HA and polycystin-2 (loop 5)–HA, and revealed protected fragments of the expected size (Figure 6) of ~8.0 kDa (Figure 8a, lanes 3 and 4) and ~5 kDa (Figure 8b, lane 2) respectively. This confirmed that loops 3 and 5 also extend into the microsomal lumen, in agreement with the immunofluorescence data. In the case of polycystin-2 (loop 3)–HA, a 4-fold higher concentration of proteinase K was necessary to achieve complete digestion. The resulting protected fragment was slightly smaller than expected (Figure 8a, lane 4), which could not be explained by the penetration of proteinase K into damaged microsomes because calreticulin levels remained unaffected (Figure 8a, lower panel, compare lanes 3 and 4). The fact that protected fragments of the expected size were detected demonstrates that the predicted cleavage sites (Figure 6) between amino acids 492 and 503 and 571 and 598 respectively, were accessible to proteinase K. This in turn suggests a cytoplasmic orientation of loops 2 and 4. Indeed no protected fragment were detected with microsomes of COS-7 cells synthesizing polycystin-2 (loop 2)–HA and (loop 4)–HA (results not shown). Taken together, these protease protection assays confirm our immunofluorescence data and strongly support a topology model for polycystin-2 in which loops 1, 3 and 5 extend into the lumen of the ER (or the extracellular space), whereas loops 2 and 4 extend into the cytosol (Figure 9). Furthermore, our immunofluorescence data confirm the cytoplasmic orientation of the N- and C-termini of polycystin-2 (Figure 9).
PKD2 is one of the two genes mutated in patients with ADPKD. Despite extensive efforts, it remains unclear how mutations lead to PKD. PKD2 encodes the non-selective cation channel polycystin-2, a member of the TRP family of cation channels. Since structural information provides clues on the function of polycystin-2 and will help to better characterize disease-associated mutations, in the present study we elucidate the topology of this calcium channel.
Topology studies of integral membrane proteins are ideally carried out with the full-length protein, e.g. by inserting specific immunological epitopes or N-glycosylation sites into the protein. The location of the inserted domains is subsequently determined by the access of the epitope to the respective antibody in non-permeabilized and permeabilized cells, and by the access of the novel glycosylation sites to the glycosylation machinery which is exclusively located in the lumen of the ER and Golgi apparatus. Our initial attempts to elucidate the topology of polycystin-2 by using the latter approach failed because polycystin-2 became increasingly unstable the more of the endogenous N-glycosylation sites were removed, a typical phenomenon attributed to the loss of structural integrity of the protein . In light of the very limited structural data for polycystin-2 we chose the strategy to generate progressively shorter polycystin-2 proteins with an HA epitope at their very C-terminus. One of the possible drawbacks of our approach could be an altered topology of the truncated proteins. This objection cannot be held against our topology study because the cytoplasmic orientation of the N-terminus was demonstrated both by immunofluorescence in the context of the full-length protein, and by the identification of a protected fragment for polycystin-2 (loop 1)–HA in the proteinase K protection assay. The cytoplasmic location of the N-terminus confirms published data obtained with the pathogenic polycystin-2 mutant protein R742X [10,25]. Finally the observation that loop 1 was detected in the lumen of the ER or extending into the extracellular space in polycystin-2 constructs of different lengths and independently of the presence of a C-terminal HA epitope indicates that neither the C-terminal deletions nor the HA epitope altered the overall topology of polycystin-2.
Our model that the N-terminus, the C-terminus, and loops 2 and 4 of polycystin-2 extend into the cytoplasm, whereas loops 1, 3 and 5 are located in the lumen of the ER, is in agreement with two hydrophobicity plot-based structural predictions of polycystin-2 ( and Swiss-Prot database accession number Q13563). As a matter of fact our experimental data solve a discrepancy between both predictions regarding the exact position of transmembrane domain 4 (Figure 1). We show that the constructs truncated at amino acid positions 573–577 were accessible to the anti-(HA epitope) antibody upon digitonin treatment (results not shown), which indicates that this part of loop 4 extends into the cytoplasm and cannot be part of the transmembrane domain 4 as suggested . Our experimental data rather support the Swiss-Prot database model which proposes that transmembrane domain 4 ends at amino acid residue 571.
Our data also confirm the predicted cytoplasmic location of the C-terminus of full-length polycystin-2. A cytoplasmic orientation of the C-terminus is in agreement with the fact that this portion of polycystin-2 interacts with many cytosolic proteins . A similar argument holds true for the cytoplasmic orientation of the N-terminus of polycystin-2 which interacts with cytoplasmic proteins such as α-actinin and KIF3B (kinesin family member 3B) [27,28]. The following additional findings support the orientation of the N- and C-terminus in the cytoplasm: (i) phosphorylation sites have been identified in the N-terminus  and C-terminus [22,25] of polycystin-2, (ii) a ciliary trafficking motif has been identified in the N-terminus , and (iii) a retention signal for the ER has been identified in the C-terminus of polycystin-2 . The proposed orientation of loop domain 5 also fits with previous data. Addition of an antibody directed against loop 5 of murine polycystin-2 abrogates the flow-induced calcium response of embryonic kidney cells, which is attributed to a functional plasma membrane complex of polycystin-1 and polycystin-2 .
In summary, the present study provides the first experimental evidence for the topology of polycystin-2. It constitutes another step towards a better characterization of the function of polycystin-2 and will improve our understanding of mutations in PKD2.
Helen Hoffmeister, Anna-Rachel Gallagher, Anne Rascle and Ralph Witzgall designed the experiments; Helen Hoffmeister and Anna-Rachel Gallagher performed the experiments; Helen Hoffmeister, Anna-Rachel Gallagher, Anne Rascle and Ralph Witzgall analysed the experiments; and Helen Hoffmeister, Anne Rascle and Ralph Witzgall wrote the manuscript.
This work was supported by the German Research Council [programme project SFB 699].
Uwe de Vries (Institute for Molecular and Cellular Anatomy, University of Regensburg, Regensburg, Germany) was instrumental in taking pictures at the confocal laser-scanning microscope. We thank Elisabeth Besl and Larissa Osten (Institute for Molecular and Cellular Anatomy, University of Regensburg, Regensburg, Germany) for expert technical assistance. We are grateful for the gift of the YCB9 antiserum from Yiqiang Cai and Stefan Somlo (Section of Nephrology, Yale University School of Medicine, New Haven, CT, U.S.A.), and for the generation of the anti-polycystin-2 peptide antiserum by Bernhard Dobberstein (Center of Molecular Biology, University of Heidelberg, Heidelberg, Germany). Antje Zenker and Ton Maurer skillfully arranged the Figures.
Abbreviations: ADPKD, autosomal-dominant polycystic kidney disease; Cy3, indocarbocyanine; ER, endoplasmic reticulum; HA, haemagglutinin; HRP, horseradish peroxidase; PKD, polycystic kidney disease; PNGase F, peptide N-glycosidase F; TRP, transient receptor potential
- © The Authors Journal compilation © 2011 Biochemical Society